Tariffs Start Hitting Profits

A tariff stopped being a talking point this week when Tecnoglass cut its own profit outlook and said a new United States duty on finished aluminum windows would take about $50 million out of 2026 adjusted earnings before interest, taxes, depreciation, and amortization. The company lowered that 2026 profit range to $225 million to $245 million even though it said first-quarter demand and backlog were still strong. (financecolombia.com, markets.businessinsider.com) That detail matters because Tecnoglass is not a marginal exporter trying to break into the market. The Barranquilla-based company built a business around selling architectural glass and aluminum-framed windows into the United States, so a 10% border charge lands directly on one of its core products. (financecolombia.com, finance.yahoo.com) The company’s message was unusually blunt: the guidance cut was “entirely” tied to the revised tariff framework, not to weaker orders, not to a construction slowdown, and not to an operational miss. In other words, the factory kept doing its job and the policy changed the math anyway. (seekingalpha.com, marketchameleon.com) That is how tariffs start showing up in earnings season. They do not have to kill sales overnight to hurt a company; they only have to shave enough off each shipment that margins compress before contracts, prices, and sourcing can be reset. (markets.businessinsider.com, financecolombia.com) A second example is unfolding in pharmaceuticals, where the White House announced a 100% tariff on patented pharmaceutical products and ingredients under Section 232 of the Trade Expansion Act. The administration said the measure is tied to national security and public-health supply chains, with tariffs taking effect in 120 days for certain large companies and 180 days for smaller companies. (whitehouse.gov, whitehouse.gov) RSM says the immediate problem is not just the headline rate but the compliance puzzle underneath it. Companies now have to determine whether a medicine is covered by a valid unexpired United States patent, whether it appears in the Food and Drug Administration’s Orange Book or Purple Book, and whether a related ingredient also falls inside the tariff net. (realeconomy.rsmus.com, whitehouse.gov) That makes this different from a simple customs surcharge on a container of steel bolts. A branded drug can carry patent, licensing, transfer-pricing, and manufacturing-location questions all at once, so the tariff decision quickly turns into a legal, tax, and supply-chain decision. (realeconomy.rsmus.com, ropesgray.com) The White House also built in pressure points instead of a single flat rule for everyone. The proclamation includes special treatment for products of the United Kingdom and phased timing that gives companies a narrow window to rethink import routes, customs valuation, and where final production happens. (whitehouse.gov, realeconomy.rsmus.com) Put the two cases together and the pattern is clear. In windows, the tariff has already cut a public company’s 2026 profit guidance; in pharmaceuticals, companies are still racing through classifications and exemptions before the full cost lands. (financecolombia.com, realeconomy.rsmus.com) That is the shift from political signaling to operational pain. Once a tariff moves from a speech into a customs entry, it stops being an argument about trade theory and starts becoming a lower earnings guide, a repriced contract, or a rushed decision about where to make the next batch. (markets.businessinsider.com, whitehouse.gov)